Wakamoto Pharmaceutical Co (TSE:4512) COGS-to-Revenue : 0.00 (As of Sep. 2024)

View and export this data going back to 1949. Start your Free Trial

What is Wakamoto Pharmaceutical Co COGS-to-Revenue?

Wakamoto Pharmaceutical Co's Cost of Goods Sold for the three months ended in Sep. 2024 was 円0 Mil. Its Revenue for the three months ended in Sep. 2024 was 円0 Mil.

Wakamoto Pharmaceutical Co's COGS to Revenue for the three months ended in Sep. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Wakamoto Pharmaceutical Co's Gross Margin % for the three months ended in Sep. 2024 was N/A%.

Wakamoto Pharmaceutical Co COGS-to-Revenue Historical Data

The historical data trend for Wakamoto Pharmaceutical Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wakamoto Pharmaceutical Co COGS-to-Revenue Chart

Wakamoto Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

Get a 7-Day Free Trial

0.43

0.50

0.48

0.53

Wakamoto Pharmaceutical Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial															0.53	0.59	0.52	0.51	-

Wakamoto Pharmaceutical Co COGS-to-Revenue Calculation

Wakamoto Pharmaceutical Co's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4138.701	/	7738.425
	=	0.53

Wakamoto Pharmaceutical Co's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Wakamoto Pharmaceutical Co (TSE:4512) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Wakamoto Pharmaceutical Co's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Wakamoto Pharmaceutical Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Wakamoto Pharmaceutical Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Wakamoto Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wakamoto Pharmaceutical Co Ltd (TSE:4512) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330

Website

http://www.wakamoto-pharm.co.jp

Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.

Wakamoto Pharmaceutical Co Headlines

No Headlines